Accretive Wealth Partners’s AbbVie ABBV Stock Holding History

Accretive Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$458K	Buy	1,822 +466	+34%	+$100K	0.11%	125
2026 Q1	$295K	Buy	+1,356	New	+$301K	0.08%	143

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Accretive Wealth Partners's ABBV Position: Q2 2026 in Review

Accretive Wealth Partners increased its AbbVie (ABBV) stake by 34% in Q2 2026, buying an estimated $100K and bringing the position to 1,822 shares worth $458K. The position accounts for 0.11% of the portfolio, ranked #125.

Accretive Wealth Partners first reported a position in ABBV in Q1 2026 and has held it in 2 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Accretive Wealth Partners held 1,822 shares of AbbVie worth $458K as of Q2 2026.
Accretive Wealth Partners bought 466 AbbVie shares in Q2 2026, an estimated $100K.
AbbVie made up 0.11% of Accretive Wealth Partners's portfolio in Q2 2026, its #125 holding.
Accretive Wealth Partners first reported a position in AbbVie in Q1 2026 and has held it in 2 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Accretive Wealth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.